Pipeline Overview

G1 is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. Our drug candidates were designed to be administered in combination with many conventional and emerging cancer therapeutics.

We own worldwide commercial rights to trilaciclib (G1T28), G1T38 and G1T48, and have more than 115 U.S. and international patents and pending patent applications covering our product development programs.